MAP2K7 and chronic myelogenous leukemia, BCR-ABL1 positive: In CML cells, the BCR/ABL oncoprotein has proliferative effects activating the Ras/Raf/MEK/ERK, JAK/STAT and PI3K/Akt pathways [27-30].